| Mark Walker, | |
|
2730 Pacific Blvd Se, Albany, OR 97321-5075 | |
| (541) 967-3866 | |
| (541) 812-8807 |
| Full Name | Mark Walker |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 2730 Pacific Blvd Se, Albany, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851759997 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | (* (Not Available)) | Secondary |
| 1041C0700X | Social Worker - Clinical | L11278 (Oregon) | Primary |
| Entity Name | Yamhill County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891821500 PECOS PAC ID: 3274421169 Enrollment ID: O20040419001782 |
News Archive
MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.
ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.
An international group of researchers led by the Peninsula Medical School and the University of Exeter have for the first time identified changes in sex hormones associated with BPA exposure in men, in a large population study. The study results are published in the latest issue of Environmental Health Perspectives.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Walker, Po Box 100, Albany, OR 97321-0031 Ph: (541) 967-3866 | Mark Walker, 2730 Pacific Blvd Se, Albany, OR 97321-5075 Ph: (541) 967-3866 |
News Archive
MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.
ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.
An international group of researchers led by the Peninsula Medical School and the University of Exeter have for the first time identified changes in sex hormones associated with BPA exposure in men, in a large population study. The study results are published in the latest issue of Environmental Health Perspectives.
› Verified 8 days ago